NMD4C and MDC are pleased to invite you to a CPD-accredited webinar Changes in the Therapeutic Landscape for Spinal Muscular Atrophy. NMD4C and MDC are providing organizational and technical support. This webinar is supported by Novartis through a restricted educational sponsorship with no involvement or influence on program content.

Speakers:

• Dr. Rashmi Kothary (Chair) | Maternal transfer of disease modifying therapies for SMA
  Senior Scientist, Ottawa Hospital Research Institute (OHRI) & Professor, University of Ottawa

• Dr. Hugh McMillian | Role of SMN protein on the developing brain and motor unit.
  Neuromuscular Specialist, Children’s Hospital of Eastern Ontario (CHEO) & Professor, Pediatric Neurology, University of Ottawa 

Learning Objectives:

• To better understand the need for early treatment in SMA.
• To assess whether maternal transfer of therapies is a viable approach in SMA.
• Review what is known about the role of SMN protein on the developing brain.
• Discuss rapidity of symptom onset in 2xSMN2 copy patients and the need for earlier treatment initiation.

The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

If you have any questions, please contact our Network Manger, Erin Beattie